Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) are expected to face another delay in launching their new Alzheimer's drug, lecanemab, in the EU after the European Commission on Friday asked the ...

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other S&P 500 stocks. 2024 was a memorable year for the broad market index, which posted a gain ...

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for Alzheimer’s disease, providing a response after a meeting next month.

Biogen Pharmachem Industries Ltd share price was down by -0.86% from the previous closing price of ₹1.16. Who are peers of Biogen Pharmachem Industries Ltd? The peers of Biogen Pharmachem ...

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

After hours: 7:30:46 p.m. EST ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.